Skip to main content

Peer Review reports

From: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Original Submission
14 Apr 2020 Submitted Original manuscript
17 Apr 2020 Author responded Author comments - Anja Gäckler
Resubmission - Version 2
17 Apr 2020 Submitted Manuscript version 2
7 May 2020 Reviewed Reviewer Report
22 May 2020 Reviewed Reviewer Report
28 May 2020 Reviewed Reviewer Report
29 Jul 2020 Author responded Author comments - Anja Gäckler
Resubmission - Version 3
29 Jul 2020 Submitted Manuscript version 3
5 Aug 2020 Reviewed Reviewer Report
20 Aug 2020 Reviewed Reviewer Report
27 Aug 2020 Reviewed Reviewer Report
16 Nov 2020 Author responded Author comments - Anja Gäckler
Resubmission - Version 4
16 Nov 2020 Submitted Manuscript version 4
19 Nov 2020 Author responded Author comments - Anja Gäckler
Resubmission - Version 5
19 Nov 2020 Submitted Manuscript version 5
25 Nov 2020 Author responded Author comments - Anja Gäckler
Resubmission - Version 6
25 Nov 2020 Submitted Manuscript version 6
Publishing
26 Nov 2020 Editorially accepted
6 Jan 2021 Article published 10.1186/s12882-020-02190-0

You can find further information about peer review here.

Back to article page